Analytic Investors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Analytic Investors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-71,151	Closed	-$1.85M	–	640
2015 Q1	$1.85M	Sell	71,151 -37,733	-35%	-$692K	0.03%	282
2014 Q4	$1.4M	Buy	+108,884	New	+$1.36M	0.02%	302

Other funds holding HZNP

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

LPC

Lone Pine Capital Greenwich, Connecticut $16.4B AUM 99.7% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Analytic Investors's HZNP Position: Q2 2015 in Review

Analytic Investors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2015, closing a stake of 71,151 shares — an estimated $1.85M sold.

Analytic Investors first reported a position in HZNP in Q4 2014 and held it in 2 quarters. The position peaked at $1.85M in Q1 2015. 213 funds tracked by Wall St. Rank hold HZNP as of Q2 2015.

Analytic Investors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2015 after selling out during the quarter.
Analytic Investors sold 71,151 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2015, an estimated $1.85M.
Analytic Investors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2014 and held it in 2 quarters.
Analytic Investors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.85M in Q1 2015.
213 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2015.

Based on Analytic Investors's 13F filing for Q2 2015, filed 12 Aug 2015.